Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows strong financial performance with a significant increase in operating income and cash reserves. The company has a strategic plan with robust revenue growth projections and a focus on expanding its product pipeline. The Q&A session reveals confidence in AMVUTTRA's market positioning and growth potential, despite competitive threats. While there are increased expenses, they are tied to growth initiatives. The sentiment is positive, supported by strong financial metrics and optimistic guidance, suggesting a likely stock price increase in the short term.
Key Financial Performance
Total net revenues from AMVUTTRA and ONPATTRO Over $900 million in Q1 2026, marking a significant milestone for Alnylam.
Combined net product revenues $1.036 billion in Q1 2026, up 121% year-over-year and 4% over Q4 2025, driven by strong commercial execution and product uptake.
Rare disease net revenue $126 million in Q1 2026, up 15% year-over-year, driven by increased patient demand, partially offset by higher gross-to-net deductions.
Global TTR net revenues $910 million in Q1 2026, up 6% from Q4 2025 and 153% year-over-year, driven by strong momentum in AMVUTTRA and increased patient demand.
U.S. TTR revenues Grew 9% versus Q4 2025 and more than 230% year-over-year, reflecting continued growth in patient demand.
International TTR revenues Declined $7 million from Q4 2025 due to updated pricing in Germany but grew 35% year-over-year, with strong performance in Japan and PN markets.
Collaboration revenue $82 million in Q1 2026, a 17% decrease compared to Q1 2025, primarily due to a $30 million milestone payment received in Q1 2025.
Royalty revenue $49 million in Q1 2026, representing an 85% increase compared to Q1 2025, driven by higher global LEQVIO sales.
Gross margin on product sales 80% in Q1 2026, a 5% decrease compared to Q1 2025, due to increased royalties on AMVUTTRA and higher revenues.
Non-GAAP R&D expenses $335 million in Q1 2026, up 39% year-over-year, driven by costs associated with ongoing Phase III clinical studies and early pipeline investments.
Non-GAAP SG&A expenses $283 million in Q1 2026, up 36% year-over-year, driven by investments in AMVUTTRA launch and scaling organizational support.
Non-GAAP operating income $339 million in Q1 2026, more than 4x increase compared to Q1 2025, driven by strong top-line results.
Cash, cash equivalents, and marketable securities $3 billion as of Q1 2026, up from $2.9 billion at the end of 2025, driven by strong operating performance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AMVUTTRA and ONPATTRO combined revenues: Achieved over $900 million in total net revenues in Q1 2026.
New investigational medicines: Progressed pipeline including vutrisiran and zilebesiran; initiated Phase I trial of ALN-2232 targeting ACVR1C.
New transformative medicines: Committed to delivering at least 2 new transformative medicines beyond TTR with blockbuster potential by 2030.
Global TTR net revenues: Reached $910 million in Q1 2026, up 6% from Q4 and 153% year-over-year.
Rare disease portfolio: Generated $126 million in net revenue, up 15% year-over-year.
International market access for AMVUTTRA: Positive reimbursement milestones in Europe, including launches in Austria, the U.K., Switzerland, and Italy.
Adherence and persistence to vutrisiran: Real-world data showed greater than 93% adherence and over 85% persistence for more than a year.
Gross margin on product sales: Achieved 80% gross margin in Q1 2026, though decreased by 5% compared to Q1 2025 due to increased royalties.
Non-GAAP operating income: Achieved $339 million, a more than 4x increase compared to last year.
Alnylam 2030 vision: Focused on three pillars: global leadership in TTR, sustainable innovation, and scaling with discipline for durable growth.
Expansion of TRITON-CM study: Increased enrollment by approximately 500 patients to mitigate low event rates and maintain timelines.
AI-enabled partnerships: Collaborations with Viz.ai and American Heart Association to facilitate earlier diagnosis and treatment of ATTR-CM.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Access and Pricing Challenges: Revenues outside the U.S. declined due to updated pricing in Germany following the ATTR-CM launch, which could impact international revenue growth.
Regulatory and Reimbursement Hurdles: The company faces challenges in achieving favorable health technology assessment outcomes and reimbursement milestones in international markets, which are critical for expanding patient reach.
Adherence and Persistence Risks: While adherence to vutrisiran is high, there is a risk of lower adherence and persistence compared to clinical trial settings, which could impact long-term revenue.
Supply Chain and Manufacturing Costs: Increased royalties on AMVUTTRA sales to Sanofi and the resetting of royalty rates each calendar year could lead to decreased gross margins over time.
Clinical Trial Enrollment and Event Rates: The TRITON-CM study faces potential risks of low event rates due to milder disease in enrolled patients, which could delay study outcomes and regulatory approval timelines.
Economic and Insurance Dynamics: Customary insurance reauthorization dynamics and fewer shipping weeks in Q1 impacted U.S. revenue growth, highlighting potential vulnerabilities in revenue consistency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year Financial Guidance: The company is reiterating its full-year financial guidance, reflecting confidence in the AMVUTTRA CM launch and the strength of its overall portfolio. The guidance assumes significantly higher quarter-on-quarter revenue growth for the remainder of the year to achieve $4.4 billion to $4.7 billion in TTR product sales.
TTR Revenue Growth: The company expects more substantial quarter-over-quarter growth in TTR revenues, both in the U.S. and globally, over the balance of the year. This includes continued growth in patient demand and international market access.
Pipeline Development: The company plans to deliver at least two new transformative medicines beyond TTR with blockbuster potential by 2030. It also aims to achieve RNAi delivery to at least 10 tissue types with over 40 programs in the clinic by the end of 2030.
TRITON-CM Phase III Study: Enrollment for the TRITON-CM Phase III study is proceeding faster than expected. The company plans to expand enrollment by approximately 500 patients to mitigate the risk of low event rates while maintaining or potentially accelerating timelines. A launch is projected by 2030, assuming positive data and regulatory approval.
TRITON-PN Phase III Trial: The TRITON-PN Phase III trial in hereditary ATTR polyneuropathy is ongoing and, if successful, has the potential to support approval in this indication by 2028.
AMVUTTRA ATTR-CM Launch: The company is focused on expanding the prescriber base, sustaining category growth, and maintaining high adherence and persistence rates for AMVUTTRA. It is also advancing AI-enabled partnerships to facilitate earlier diagnosis and treatment.
Clinical Readouts and Milestones: Several clinical readouts are expected in the second half of 2026, including Phase I data for ALN-HTT02 in Huntington's disease and ALN-2232 for obesity and weight management. Phase II results for ALN-6400 in hereditary hemorrhagic telangiectasia will also be shared.
R&D Investment: The company plans to invest approximately 30% of revenues in non-GAAP R&D through 2030 to support the development of new medicines.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the experience with first-line and second-line use of AMVUTTRA?
A:Second-line use is normalizing as physicians transition patients progressing on stabilizers to AMVUTTRA. First-line use is increasing as physicians gain experience with the drug. The company is focusing on expanding the prescriber base to strengthen first-line positioning.
Q:What was the impact of selling weeks and inventory on Q1 results for AMVUTTRA in the U.S.?
A:Q1 U.S. results showed $59 million in growth, primarily demand-driven. There was a positive inventory impact offset by pricing adjustments. The number of Wednesdays in the quarter (12 compared to 14 in Q4) affected comparisons. Sequential improvement in demand was observed from January to March.
Q:How does the company view the upcoming competitor study on silencer-stabilizer combination therapy?
A:The company expects the competitor study to show positive results, validating the silencing mechanism. They believe their own HELIOS-B results already demonstrate the effectiveness of silencing mechanisms in combination therapy. They are confident in their positioning with AMVUTTRA and the upcoming TRITON-CM study.
Q:What is the company's perspective on the potential failure of the competitor's silencer-stabilizer combination study?
A:The company acknowledges differences between their RNAi mechanism and the competitor's ASO mechanism. They believe their studies, such as HELIOS-B and TRITON-CM, are well-designed to establish success and provide robust data. They are cautious about speculating on competitor outcomes.
Q:What are the ex-U.S. pricing dynamics for AMVUTTRA?
A:Ex-U.S. pricing dynamics involve price adjustments when launching the CM indication, impacting the PN business base. Germany had the most significant impact in Q1. Over time, CM volume is expected to offset initial price adjustments, contributing positively to growth starting in Q2.
Q:How does the company view the potential impact of another silencer entering the market on pricing?
A:The company does not anticipate significant pricing changes. They believe their established first-line access and payer relationships will sustain their position. They note that the competitor's pricing is slightly higher than theirs, and they are monitoring the situation carefully.
Q:What trends are being observed in first-line use of AMVUTTRA?
A:First-line use is increasing as physicians gain experience with AMVUTTRA. The company is focusing on expanding the prescriber base to further grow first-line use.
Q:How does the Pfizer settlement for Vyndamax impact the TTR cardiomyopathy landscape?
A:The company expects limited impact from the Pfizer settlement. They believe the shift toward treating the disease at its source with AMVUTTRA is durable and independent of pricing dynamics within the stabilizer class.
Q:What is the company's perspective on the PN competitive landscape and the impact of Medicare Part B versus Part D dynamics?
A:The company has a strong position in the PN market with over 75% market share in new patient starts. They have nearly 100% overall access and over 90% first-line access without step edits. They believe their quarterly subcutaneous regimen aligns well with patient and physician needs.
Q:What is the company's view on cemdisiran in the MG competitive landscape?
A:The company is pleased with the progress of cemdisiran in myasthenia gravis (MG). They find the data compelling and believe it will be a formidable drug for patients with unmet needs.
Q:How does the company view the potential for increased combination use in the frontline setting with generic stabilizers?
A:The company believes they are well-positioned with AMVUTTRA and the upcoming TRITON-CM study. They already have combination data in their label and are confident in their ability to maintain and grow their market position.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the sequential headwind percentage related to selling weeks, as well as the exact pricing dynamics that might emerge with the entry of another silencer in the market. They also did not speculate on the potential failure scenarios for the competitor's silencer-stabilizer combination study.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
ALN HTT
American
DDG baseline
II trial
Phase II
Phase III
Pushkal
RNAi
Sanofi
TTR revenue
Today
adherence persistence
area
biotech
capability
care pathway
diagnosis
disease awareness
dysfunction
endpoint event
event rate
healthcare
interest
nucresiran
pace enrollment
physician experience
pillar
preference
prescriber line
readout
reminder
risk event
sale course
success
use
vutrisiran
wave medicine
ALNY Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call shows strong financial performance with a significant increase in operating income and cash reserves. The company has a strategic plan with robust revenue growth projections and a focus on expanding its product pipeline. The Q&A session reveals confidence in AMVUTTRA's market positioning and growth potential, despite competitive threats. While there are increased expenses, they are tied to growth initiatives. The sentiment is positive, supported by strong financial metrics and optimistic guidance, suggesting a likely stock price increase in the short term.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
ALNY Slides
ALNY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
